

# Calcium Folate Treatment of Spastic Paraplegia 56

NCT06478238

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Early Phase 1
<b>Sponsor</b>	Shanghai 6th People's Hospital
<b>Enrollment</b>	10 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Patients meet the clinical diagnostic standard of hereditary spastic paraplegia (HSP);
- Spastic paraplegia type 56 (SPG56) was diagnosed by CYP2U1 pathogenic mutation;
- Patients are willing to participate in clinical trials and able to understand and comply with the research program.

### Exclusion (6)

- Patients are allergic to the drugs involved in the study;
- Other neurological diseases likely affecting the evaluation of study treatment;
- Other medical conditions such as: heart disease, tumor, blood disease, liver disease, kidney disease, etc. in the past 1 year;
- Pregnancy or lactating women or subjects who are unable to use appropriate contraception during the trial;
- Participating in another study drug trial and used the investigational drug in the past 30 days;
- ... and 1 more (see full listing online)

## Locations (1 total)

---

Shanghai 6th People's Hospital, Shanghai, Shanghai Municipality, China